Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 10, 2003, Pages 1881-1888

  Kontush, Anatol ^a   Chantepie, Sandrine ^b   Chapman, M John ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

Enzymatic activities; HDL subfractions; LDL oxidation; Physicochemical properties; Small, dense HDL

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALKADIENE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; COPPER; HIGH DENSITY LIPOPROTEIN; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROTEIN SUBUNIT; THIOBARBITURIC ACID;

ARTICLE; ATHEROGENESIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY GRADIENT; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; ENZYME MECHANISM; FAST PROTEIN LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIPID OXIDATION; MALE; NORMAL HUMAN; OXIDATION; OXIDATIVE STRESS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; SERUM; STATISTICAL SIGNIFICANCE; ULTRACENTRIFUGATION;

ANTIOXIDANTS; COPPER; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0141885327     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000091338.93223.E8     Document Type: Article

References (43)

1. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med. 2001; 11:93-102.
2. Gaut JP, Heinecke JW. Mechanisms for oxidizing low-density lipoprotein: insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med. 2001;11:103-112.
3. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med. 2001;11:155-161.
4. Francis GA. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta. 2000;1483: 217-235.
5. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-480.
6. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis. 2002;(suppl 3):57-68.
7. Goyal J, Wang K, Liu M, Subbaiah PV. Novel function of lecithin-cholesterol acyltransferase. J Biol Chem. 1997;272:16231-16239.
8. Chen N, Liu Y, Greiner CD, Holtzman JL. Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides. J Lab Clin Med. 2000;136:58-65.
9. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495-508.
10. Boisfer E, Stengel D, Pastier D, Laplaud PM, Dousset N, Ninio E, Kalopissis AD. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J Lipid Res. 2002;43:732-741.
11. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:1023-1028.
12. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14:55-61.
13. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994;33:832-839.
14. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins: pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19(suppl A):A24-A30.
15. Kontush A, Chancharme L, Escargueil-Blanc I, Therond P, Salvayre R, Negre-Salvayre A, Chapman MJ. Mildly oxidized LDL particle subspecies are distinct in their capacity to induce apoptosis in endothelial cells: role of lipid hydroperoxides. FASEB J. 2003;17:88-90.
16. von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 1994;5:404-416.
17. Lamarche B, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta. 1999;286:145-161.
18. Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1450-1455.
19. Graham A, Hassall DG, Rafique S, Owen JS. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 1997;135:193-204.
20. Yoshikawa M, Sakuma N, Hibino T, Sato T, Fujinami T. HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clin Biochem. 1997;30:221-225.
21. Huang JM, Huang ZX, Zhu W. Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein. Clin Biochem. 1998;31:537-543.
22. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol. 1999;19:2226-2233.
23. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res. 1981;22:339-358.
24. Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids: relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:786-796.
25. Raveh O, Pinchuk I, Fainaru M, Lichtenberg D. Kinetics of lipid peroxidation in mixtures of HDL and LDL, mutual effects. Free Radic Biol Med. 2001;31:1486-1497.
26. Schnitzer E, Pinchuk I, Bor A, Fainaru M, Lichtenberg D. The effect of albumin on copper-induced LDL oxidation. Biochim Biophys Acta. 1997; 1344:300-311.
27. Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS. High-density lipoprotein composition and paraoxonase activity in type I diabetes. Clin Sci (Lond). 2001;101:659-670.
28. Chung J, Abano D, Byrne R, Scanu AM. In vitro mass: activity distribution of lecithin-cholesterol acyltransferase among human plasma lipoproteins. Atherosclerosis. 1982;45:33-41.
29. Chancharme L, Therond P, Nigon F, Lepage S, Couturier M, Chapman MJ. Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. Arterioscler Thromb Vasc Biol. 1999;19:810-820.
30. Dentan C, Lesnik P, Chapman MJ, Ninio E. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. Arterioscler Thromb. 1994;14:353-360.
31. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892-904.
32. Schiavon R, Battaglia P, De Fanti E, Fasolin A, Biasioli S, Targa L, Guidi G. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta. 2002;324:39-44.
33. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res. 2002;43:256-263.
34. Kunitake ST, Jarvis MR, Hamilton RL, Kane JP. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci USA. 1992;89:6993-6997.
35. De Geest B, Stengel D, Landeloos M, Lox M, Le Gat L, Collen D, Holvoet P, Ninio E. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase: comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler Thromb Vasc Biol. 2000;20: E68-E75.
36. Schaefer EJ, Foster DM, Jenkins LL, Lindgren FT, Berman M, Levy RI, Brewer HB Jr. The composition and metabolism of high density lipoprotein subfractions. Lipids. 1979;14:511-522.
37. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res. 2003;44:780-792.
38. McCall MR, La Belle M, Forte TM, Krauss RM, Takanami Y, Tribble DL. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. Biochim Biophys Acta. 1999;1437:23-36.
39. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A. 1992;89:10316-10320.
40. Leroy A, Dallongeville J, Fruchart JC. Apolipoprotein A-I-containing lipoproteins and atherosclerosis. Curr Opin Lipidol. 1995;6:281-285.
41. Davidson WS, Rodrigueza WV, Lund-Katz S, Johnson WJ, Rothblat GH, Phillips MC. Effects of acceptor particle size on the efflux of cellular free cholesterol. J Biol Chem. 1995;270:17106-17113.
42. Hahnel D, Beyer K, Engelmann B. Inhibition of peroxyl radical-mediated lipid oxidation by plasmalogen phospholipids and alpha-tocopherol. Free Radic Biol Med. 1999;27:1087-1094.
43. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT. A randomized controlled trial. JAMA. 2001; 285:1585-1591.